Ethnic minority communities and the elderly called upon to bolster the fight against coronavirushttps://t.co/S43N3krrDY
— Novavax (@Novavax) October 13, 2020
Today we announced the formation of a dedicated development unit & leadership team focused advancing NanoFlu, our #influenza #vaccine program, through licensure. Read our release for more details: https://t.co/eRg5FiTbiG #flu $NVAX pic.twitter.com/JLZw8MkXQJ
— Novavax (@Novavax) October 13, 2020
Thanks for having us on! https://t.co/zRQARb2bWv
— Novavax (@Novavax) September 28, 2020
For registration information and details, please see today’s press release here: https://t.co/m28gh6PHtA pic.twitter.com/ylOkHm1IGd
— Novavax (@Novavax) September 28, 2020
Yesterday, we welcomed @GovLarryHogan @DrMichelleBIO & distinguished guests for a lab tour & update on our journey toward a #safe and #effective #vaccine against #COVID-19. To read their remarks or view the video, read our announcement: https://t.co/incfsX7tQ1 @IamBiotech pic.twitter.com/NO3bASZup1
— Novavax (@Novavax) September 25, 2020
We have just announced initiation of the first Phase 3 trial for #NVXCoV2373, our #COVID-19 candidate #vaccine. Read our announcement to learn more: https://t.co/ECY7DceFNo pic.twitter.com/Ig8XizXUho
— Novavax (@Novavax) September 24, 2020
We are pleased to announce an expansion of our agreement with @SerumInstIndia to manufacture antigen for #NVXCoV2373, our #COVID-19 #vaccine candidate. Read today’s announcement to learn more: https://t.co/qOYmaBhim9 pic.twitter.com/0cEFT4NCKA
— Novavax (@Novavax) September 15, 2020
#WeStandWithScience @Pfizer @JNJNews @AstraZeneca @Sanofi @Moderna_tx @BioNTech_Group @GSK @Merck pic.twitter.com/9uzjqrCtPr
— Novavax (@Novavax) September 8, 2020
This morning, we joined 8 other leading biopharmaceutical companies in stating our unwavering commitment to making safety and well-being of vaccinated individuals our top priority in developing our COVID-19 vaccine. #NVX-CoV2373 #WeStandWithScience https://t.co/v6OAY3CJaB pic.twitter.com/nNtckX4Eyw
— Novavax (@Novavax) September 8, 2020
We invite and encourage the public and the biopharma and life science community to join us as #WeStandWithScience @Pfizer @JNJNews @AstraZeneca @Sanofi @Moderna_tx @BioNTech_Group @GSK @Merck #vaccines #COVID19 https://t.co/mniynbtBzx pic.twitter.com/QgtQAFoh7J
— Novavax (@Novavax) September 8, 2020
We are pleased to announce the prestigious New England Journal of Medicine has published the @phase1 data for our #COVID19 #vaccine candidate, #NVXCoV2373. @NEJM
To learn more, read our release here: https://t.co/rtVBZCdWqJ.#novavax2020 pic.twitter.com/PSeFjf0z2Q— Novavax (@Novavax) September 2, 2020
We are pleased to reach an agreement in principle with the Government of Canada to supply up to 76 million doses of #NVXCoV2373. Read more here: https://t.co/kcvBEnbJvU. #COVID19 #vaccine #Novavax2020 pic.twitter.com/bEHAM4hGkq
— Novavax (@Novavax) August 31, 2020
Today, members of our delegation in the Czech Republic stopped by the @USEmbassyPrague to meet with Ambassador King and share progress on our #vaccine production plant in #Bohumil. Thank you, @USAmbPrague for your hospitality. #NVXCoV2373 #COVID19 pic.twitter.com/2Y1iRhFlxX
— Novavax (@Novavax) August 27, 2020
Thank you Minister @KarelHavlicek_ for taking the time to meet with our team, including our CEO Stan Erck to discuss efforts to combat #COVID19 and #production of #NVXCoV2373, our development stage #vaccine @Novavax CZ pic.twitter.com/G6pm7yavKB
— Novavax (@Novavax) August 27, 2020
Many thanks to Prime Minister @AndrejBabis for your visit to @Novavax CZ, our #vaccine production plant in Bohumil, to learn more about our plans for developing & manufacturing #NVXCoV2373 to fight #COVID19 #Novavax2020 pic.twitter.com/MCiYbKmiKl
— Novavax (@Novavax) August 26, 2020
$NVAX is very excited to announce initiation of the #phase2 portion of the Phase 1/2 clinical trial for #NVXCoV2373, our #COVID19 #vaccine . Read our news release to learn more to learn more at https://t.co/odDdtiWmB6. #novavax2020
— Novavax (@Novavax) August 24, 2020
Thanks @jchatterleycnn for taking time to have Stan to talk about our Phase 2b clinical #vaccine #trial., #NVXCoV2373 “We’re doing something unprecedented.” – Stanley C. Erck https://t.co/389XKP2Gry
— Novavax (@Novavax) August 18, 2020
Thanks @IAmBiotech for talking w/ our CEO Stan Erck about what’s needed for a #COVID #vaccine to succeed in stemming the #pandemic & exciting Ph1 results for #NVXCoV2373, our recombinant #nanoparticle vaccine candidate. Looking forward to the next conversation w/ @DrMichelleBIO! https://t.co/CytusM2FDZ
— Novavax (@Novavax) August 17, 2020
We’re pleased to share that the first Phase 2 clinical trial of #NVXCoV2373 is beginning. The Phase 2b trial initiates today in South Africa. Read our announcement here: https://t.co/YL24AWyjpW #COVID-19 #vaccine #Novavax2020 pic.twitter.com/mMUcXRXGgy
— Novavax (@Novavax) August 17, 2020
We are honored to collaborate with the #UK Government to advance #NVXCoV2373 into Phase 3 testing and provide 60 million doses for the UK. Read more here: https://t.co/XrZYcEC1QP. #COVID19 #vaccine #Novavax2020 pic.twitter.com/dAcL7Rapyk
— Novavax (@Novavax) August 14, 2020
$NVAX is proud to announce a collaboration with SK bioscience to #manufacture our #COVID19 #vaccine antigen in South Korea. #NVXCoV2373 #novavax2020
Read more here: https://t.co/NXHBuP81F8 pic.twitter.com/8vThNgfDH1— Novavax (@Novavax) August 13, 2020
Research scientists from @scrippsresearch have shared a detailed structural analysis of our recombinant #nanoparticle #vaccine candidate for #COVID19. Read about it here: https://t.co/N2LMDsayVx #NVXCoV2373 pic.twitter.com/UwVSBWKntb
— Novavax (@Novavax) August 8, 2020
$NVAX is pleased to announce a partnership with global vaccine leader @Takeda to develop, manufacture & commercialize our #COVID19 vaccine candidate, #NVXCoV2373, in Japan. To learn more, please read today's announcement here: https://t.co/QhbV2LVUBC pic.twitter.com/iSDc9EraHp
— Novavax (@Novavax) August 7, 2020
We are proud to announce a collaboration with @SerumInstIndia to develop and commercialize our #COVID19 #vaccine candidate for LMIC ; an important 1st step to ensure a global supply during worldwide pandemic. Read it here: https://t.co/vh0f19Kx7g. #NVXCoV2373 pic.twitter.com/UFOwwgbG5u
— Novavax (@Novavax) August 7, 2020
$NVAX to host conference call to discuss second quarter financial and operational results on August 10, 2020 #Earnings https://t.co/1mGt4lVAvc
— Novavax (@Novavax) August 6, 2020
$NVAX President of R&D, Dr. Gregory Glenn, joined @MariaBartiromo this morning to discuss our promising #Phase1 #vaccine data and next steps in our #COVID19 #candidate development. Watch it here: https://t.co/2jD9cQdvWC @morningsmaria #WarpSpeed #NVXCoV2373 pic.twitter.com/9gM7du0ZW0
— Novavax (@Novavax) August 5, 2020
$NVAX President of R&D, Dr. Gregory Glenn, spoke with @NYTimes about the encouraging results from our #Phase1 trial of #NVXCoV2373, our #COVID19 #Vaccine candidate. Read the article here: https://t.co/GVLO6Puw7J @carlzimmer @katie_thomas#novavax2020 pic.twitter.com/fIuVVY0x4w
— Novavax (@Novavax) August 5, 2020
Thank you @loftus for taking the time to speak with us about our exciting #Phase1 #vaccine data #NVXCoV2373 #novavax2020 https://t.co/29lAxi5HMj
— Novavax (@Novavax) August 5, 2020
Excited to announce positive, first-in-human #Phase1 data of our #COVID19 #vaccine candidate. Please read our announcement here for details: https://t.co/f7ni8d31GR #NVXCoV2373 pic.twitter.com/LYvWVIUeul
— Novavax (@Novavax) August 4, 2020
With the aid of Operation Warp Speed funding, #NVAX is committed to delivering 100 million doses of our #vaccine candidate starting by the end of the year. Thank you to @FujifilmDiosyn for hosting us with @Potus and members of the administration today. $NVAX #NVXCoV2373
— Novavax (@Novavax) July 28, 2020
$NVAX is pleased to announce an agreement with @FujifilmDiosyn for large-scale #manufacturing of our #COVID-19 candidate – #NVXCoV2373 – as part of #OperationWarpSpeed. To learn more, please read today's announcement here: https://t.co/nDtB8pxVuX pic.twitter.com/HLm9whzhFk
— Novavax (@Novavax) July 23, 2020
Yesterday, $NVAX spoke with CNN’s Richard Quest about our approach to developing a #COVID19 #vaccine. You can view the conversation here: https://t.co/1XxqeSKsud. #NVXCoV2373 pic.twitter.com/50ylgvosZN
— Novavax (@Novavax) July 8, 2020
#ICMYI Read our #WarpSpeed announcement here: https://t.co/zHYHOrkSGg pic.twitter.com/umdjREAhch
— Novavax (@Novavax) July 8, 2020
Thank you @katie_thomas @NYTimes for helping to share $NVAX #WarpSpeed #COVID #vaccine news this morning. #NVXCoV2373 Read more here: https://t.co/IAQ2lQuUfh. pic.twitter.com/AJQBKJoNox
— Novavax (@Novavax) July 7, 2020
#NVXCoV2373 https://t.co/30wNgtoLwc
— Novavax (@Novavax) July 7, 2020
We are proud to announce a collaboration under #WarpSpeed with @HHS and @DeptofDefense to accelerate our candidate #COVID #vaccine development & scale up manufacturing. @BARDA @JPEOCBRND #savinglives #NVXCoV2373
Read our announcement for details https://t.co/SbmNOjxbIq pic.twitter.com/R2LiDW0jxp— Novavax (@Novavax) July 7, 2020
Thanks @BioCentury for attending the #BIODigital panel on #COVID19 #vaccine development https://t.co/8OfYoZ5jWQ
— Novavax (@Novavax) June 11, 2020
#ICYMI: @MorningEdition spoke with $NVAX Pres. of R&D, Dr. Gregory Glenn, & our partner @emergentbiosolu to talk about at-risk manufacturing to accelerate the delivery of a #COVID19 vaccine. Listen to the replay here: https://t.co/M1tQo38x2c pic.twitter.com/g6cKS5zKT6
— Novavax (@Novavax) June 11, 2020
$NVAX is proud to join #BIODigital for a panel about #innovative COVID-19 Vaccine Development
For more details visit: https://t.co/9HDwabjECe#COVID19 #vaccine @IAmBiotech https://t.co/hRn3y3SqRF— Novavax (@Novavax) June 8, 2020
$NVAX awarded @DeptofDefense #contract for #COVID19 #vaccine. Read more here: https://t.co/GaT3WNOxfr#NVXCoV2373 #novavax2020 pic.twitter.com/G0cBXrLiZ9
— Novavax (@Novavax) June 5, 2020
#novavax2020 #MatrixM https://t.co/GQTXesbEyr
— Novavax (@Novavax) June 4, 2020
#NVXCoV2373 #novavax2020 https://t.co/fXCVIJWcqw
— Novavax (@Novavax) June 3, 2020
$NVAX mentioned in @Bisnow's article called 'Montgomery County Businesses And Organizations Do Their Part To Combat Coronavirus'. Read more: https://t.co/a3vgsdlNSl#NVXCoV2373 #novavax2020
— Novavax (@Novavax) May 29, 2020
#NVXCoV2373 #novavax2020 https://t.co/3JEaqdZ1px
— Novavax (@Novavax) May 28, 2020
$NVAX announced the expansion of large-scale global #manufacturing capacity with the purchase of Praha Vaccines in Czech Republic. Read more: https://t.co/mDOMI5ZacJ#novavax2020 pic.twitter.com/XqDbFMU2KA
— Novavax (@Novavax) May 27, 2020
#NVXCoV2373 #novavax2020 https://t.co/IeH6bJeRI0 pic.twitter.com/aEcJAp1MIM
— Novavax (@Novavax) May 26, 2020
#NVXCoV2373 #Phase1 #clinicaltrials #novavax2020 https://t.co/9LN932jjly
— Novavax (@Novavax) May 26, 2020
#NVXCoV2373 #Phase1 https://t.co/5RDiGjL1mz
— Novavax (@Novavax) May 25, 2020
$NVAX is very excited to have just announced initiation of the #phase1 portion of the Phase 1/2 clinical trial for #NVXCoV2373, our #COVID19 #vaccine . Read our news release to learn more to learn more at https://t.co/bDOaGeRtzt. #novavax2020 pic.twitter.com/5vdmjA0THI
— Novavax (@Novavax) May 25, 2020
$NVAX General Counsel @Im_herr_mann joined @JunksRadio to talk about our progress toward a #COVID19 #vaccine and our recent @CEPIvaccines funding. We’re local fans and look forward to updating the team soon. Hear John at 33:07: https://t.co/WTbuO8QUjD#NVXCoV2373 #novavax2020 pic.twitter.com/xcPkGn59rC
— Novavax (@Novavax) May 15, 2020
Gregory Glenn, MD, President of R&D spoke earlier with @emilychangtv of @technology about our #covid19 #vaccine program development. #NVXCoV2373 #novavax2020 #coronavirus https://t.co/vDVnVrutwJ
— Novavax (@Novavax) May 15, 2020
#NVXCoV2373 #novavax2020 https://t.co/v5nOvrYAjZ
— Novavax (@Novavax) May 15, 2020
$NVAX Chief Business Officer & CFO, @jtrizzino, spoke with @WUSA9 reporter @arianedatil about our #recombinant nanoparticle vaccine candidate against #COVID19, and how soon we will begin our #Phase1 #Clinicaltrial . Watch here: https://t.co/ABiGtr2xr1#NVXCov2373 #novavax2020 pic.twitter.com/0JoacHY5cG
— Novavax (@Novavax) May 14, 2020
Today $NVAX CEO Stan Erck spoke with @jimcramer / @MadMoneyOnCNBC of #NVAX receiving $384 million additional funding from @CEPIvaccines for #coronavirus #vaccine development. Watch full video at https://t.co/CeuYnK9btq.
$NVXCoV2373 #novavax2020 #COVID19 pic.twitter.com/a1mHNu2MIT
— Novavax (@Novavax) May 13, 2020
CEPI extends collaboration with Novavax to advance development and manufacture of COVID-19 vaccine
Read announcement here: https://t.co/gR757RdTho#NVXCoV2373 #novavax2020— Novavax (@Novavax) May 11, 2020
Novavax to Receive Up To $388 Million in Funding from CEPI for COVID-19 Vaccine Development & Manufacturing
Read our announcement here:https://t.co/ULtVE3HRvi#vaccine #COVID pic.twitter.com/cd46MbDHln— Novavax (@Novavax) May 11, 2020
Gregory Glenn, MD, President of R&D, speaks with @MelserWBAL about $NVAX #coronavirus vaccine candidate, #NVXCoV2373. #vaccines #novavax2020 https://t.co/u2i9n1nDe2
— Novavax (@Novavax) April 24, 2020
$NVAX to commence #COVID19 #vaccine vaccine trial with Nucleus Network. Read more: https://t.co/ag95VDovth#NVXCoV2373 #novavax2020 #coronavirus https://t.co/7gbpLCXdEE pic.twitter.com/bPEGSk7sYD
— Novavax (@Novavax) April 16, 2020
#NVXCoV2373 #vaccines #novavax2020 https://t.co/wEXliFcHpv
— Novavax (@Novavax) April 15, 2020
#coronavirus #vaccines #novavax2020 #NVXCoV2373 https://t.co/85Mqtd3Aai
— Novavax (@Novavax) April 15, 2020
#vaccines #Coronavirus https://t.co/VsaN8JV8E7
— Novavax (@Novavax) April 10, 2020
Gregory M. Glenn, M.D., President of R&D, speaks with @fox5dc about our #COVID19 #vaccine development. #NVXCoV2373 #Coronavirus #novavax2020 https://t.co/xr9BRnjj5N
— Novavax (@Novavax) April 9, 2020
$NVAX #COVID19 #vaccine development mentioned in @FiercePharma #NVXCoV2373 #novavax2020 #coronavirus https://t.co/jAexjezdvJ
— Novavax (@Novavax) April 9, 2020
$NVAX #coronavirus #vaccine development highlighted in @BioWorld article. #NVXCoV2373 #COVID19 https://t.co/X08xTQIyU5
— Novavax (@Novavax) April 9, 2020
Gregory Glenn, MD, President of R&D, spoke with @KnvulS of @NYTimes about our development of a #COVID19 #vaccine. Read more: https://t.co/i6U2WpJlGS https://t.co/QRv3FT78Yv pic.twitter.com/EbTXERUk29
— Novavax (@Novavax) April 9, 2020
$NVAX and our development of a #coronavirus #vaccine development mentioned in $NYPost #vaccines #COVID19 https://t.co/ODTIpnVRgj
— Novavax (@Novavax) April 9, 2020
#NVXCoV2373 #COVID19 https://t.co/OX3L2ZNxts
— Novavax (@Novavax) April 8, 2020
$NVAX identifies #Covid19 vaccine candidate #NVXCoV2373 and accelerates initiation of first-in-human trial to mid-May. Read our announcement https://t.co/yo7E7pgzAu.#coronavirus #novavax2020 #MatrixM pic.twitter.com/1zIXGycirY
— Novavax (@Novavax) April 8, 2020
#NanoFlu #manufacturing #vaccines https://t.co/Hj0K3m7OoR
— Novavax (@Novavax) March 31, 2020
#NanoFlu #vaccines #influenza #flu https://t.co/N8VG05oWDt
— Novavax (@Novavax) March 31, 2020
#coronavirus #COVID19 https://t.co/8pkD5sogYB
— Novavax (@Novavax) March 27, 2020
#flu #influenza #vaccines https://t.co/lTShGWbzRX
— Novavax (@Novavax) March 27, 2020
#COVID2019 #coronavirus #vaccines https://t.co/ikCP2UhueW
— Novavax (@Novavax) March 26, 2020
Zajímavé setkání s vedením společnosti @Novavax. Vyvíjí vakcínu proti covid-19 a v tom světovém závodu si vedou dobře. Mají prý vysokou účinnost a testují už na lidech. Pro nás by to bylo super, protože koupili fabriku u Prahy, a když uspějí, nebyli bychom závislí na dovozu. pic.twitter.com/x9PG6eIvOx
— Andrej Babiš (@AndrejBabis) June 12, 2020
An extraordinary structural, biophysical, and antigenic characterization of the @novavax vaccine spike protein and glycanshttps://t.co/3qeRtUNJuX
Just published @ScienceMagazine
Proud of @Sandhyareddy88 and my @scrippsresearch colleagues who did this work pic.twitter.com/e5UBuw0zE5— Eric Topol (@EricTopol) October 20, 2020
We've got the green light to proceed with the Novavax COVID-19 vaccine trial at The Nightingale Hospital in Exeter – if you've signed up to the NHS Vaccines Registry you'll be hearing from us! @NIHRSW @RDEResearch @RDEhospitals #COVID19 @NightingaleExt https://t.co/FkmsPaYKYj
— NIHR Patient Recruitment Centre: Exeter (@PRCExeter) October 5, 2020
https://twitter.com/CEPIvaccines/status/1309454975215562754
#MTCMember Novavax begins human testing of coronavirus vaccine candidate. @Novavax said it plans to have phase 1 results available by July. https://t.co/BLaZbUjNvN pic.twitter.com/T3Tz2qEyob
— MD Tech Council (@MDTechCouncil) May 26, 2020
#Novavax Is Beginning #ClinicalTrials Of Its #Coronavirus #Vaccine via @Forbes @Novavax https://t.co/I3SXZox01H
— Plexus Ventures (@PlexusVentures) May 26, 2020
Janssen's Dr. Johan Van Hoof and our partners at the world’s leading vaccine companies wrote about making a #COVID19 vaccine and learning lessons from past outbreaks for #PandemicPreparedness. Read more: https://t.co/3UnYXj36qg @GSK @Novavax @sanofipasteur @sanofi @MSDInvents pic.twitter.com/llcNxcrsql
— Janssen Global (@JanssenGlobal) May 21, 2020
.@Novavax has started clinical trials for its coronavirus vaccine (https://t.co/vhV1MX9We0).
And it's looking to build up a bigger cash cushion: https://t.co/aztiEFMnxN
— Sara Gilgore (@WBJSara) May 26, 2020
BREAKING: @NovavaxInc has inked a deal for its seasonal flu vaccine — with another Gaithersburg biotech… https://t.co/odnofgmyTv
— Sara Gilgore (@WBJSara) March 31, 2020